Join the Diabetic Retinopathy group to help and get support from people like you.
Diabetic Retinopathy News
Empagliflozin Not Tied to Risk for New Nonproliferative Diabetic Retinopathy
TUESDAY, Dec. 17, 2024 – Empagliflozin initiation is not associated with incident nonproliferative diabetic retinopathy (NPDR) compared with initiation of a dipeptidyl peptidase 4 inhibitor (DPP4i),...
Diabetes Can Damage Your Eyes' Retinas: An Expert Explains
TUESDAY, Nov. 5, 2024 – People with diabetes face a number of health challenges related to their chronic condition, and loss of vision due to retinal damage is one of them. “Diabetes can silently d...
Social Determinants of Health Affect Monitoring for Diabetic Retinopathy
MONDAY, Sept. 16, 2024 – Certain social determinants of health (SDOH) affect monitoring for diabetic retinopathy (DR), according to a study published online Sept. 12 in JAMA Ophthalmology. Azraa S....
GLP1RAs Tied to Greater Risk of Diabetic Retinopathy Progression Than SGLT2is
FRIDAY, July 26, 2024 – In patients with diabetes and established diabetic retinopathy (DR), treatment with glucagon-like peptide 1 receptor agonists (GLP1RAs) is associated with increased risks of...
Cholesterol Med Fenofibrate Might Slow Vision Loss in People With Diabetes
TUESDAY, June 25, 2024 – A well-established cholesterol-lowering drug appears to significantly slow the progression of a diabetes-related eye disease, a new trial shows. Fenofibrate (Tricor) has...
Cholesterol Med Fenofibrate Might Slow Vision Loss in People With Diabetes
TUESDAY, June 25, 2024 – A well-established cholesterol-lowering drug appears to significantly slow the progression of a diabetes-related eye disease, a new trial shows. Fenofibrate (Tricor) has...
FDA Approves Yesafili (aflibercept-jbvf), an Interchangeable Biosimilar to Eylea
May 20, 2024 – The U.S. Food and Drug Administration (FDA) has approved Yesafili (aflibercept-jbvf), an interchangeable biosimilar to Eylea (aflibercept). Aflibercept products work by inhibiting...
FDA Approves Opuviz (aflibercept-yszy), an Interchangeable Biosimilar to Eylea
May 20, 2024 – The U.S. Food and Drug Administration (FDA) has approved Opuviz (aflibercept-yszy), an interchangeable biosimilar to Eylea (aflibercept). Aflibercept products work by inhibiting...
FDA Approves Eylea HD (aflibercept) Injection 8 mg for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
TARRYTOWN, N.Y., Aug. 18, 2023 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea HD (aflibercept)...
FDA Approves Cimerli (ranibizumab-eqrn), an Interchangeable Biosimilar to Lucentis
REDWOOD CITY, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) – Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Eylea (aflibercept) Injection for Diabetic Retinopathy
TARRYTOWN, N.Y., May 13, 2019 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept) Injection to treat all...
FDA Approves Genentech’s Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy
South San Francisco, CA – March 21, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the...
FDA Approves Genentech’s Lucentis (ranibizumab) for all Forms of Diabetic Retinopathy
South San Francisco, CA – April 17, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Lucentis® ...
FDA Approves Eylea (aflibercept) for Diabetic Retinopathy in Patients with Diabetic Macular Edema
March 25, 2015 – The U.S. Food and Drug Administration today expanded the approved use for Eylea (aflibercept) injection to treat diabetic retinopathy in patients with diabetic macular edema. ...
FDA Approves Lucentis (ranibizumab) to Treat Diabetic Retinopathy in People with Diabetic Macular Edema
February 6, 2015 – The U.S. Food and Drug Administration today expanded the approved use for Lucentis (ranibizumab injection) 0.3 mg to treat diabetic retinopathy (DR) in patients with diabetic...